William C Patt

This inventor holds 8 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Deciphera Pharmaceuticals, LLC, Ceptyr, Inc., Eli Lilly and Company. Active years: 2009-2016.

USPTO Granted Patents = 8 (Patent Applications = 3)

% Patents Active = 50.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 6.6

ph-index = 6

Forward Citations = 352(Granted Patents)

Company Filing History:

6 out of 99

Deciphera Pharmaceuticals, LLC

Eli Lilly and Company

patents

where one patent can have more than one assignee

Years Active: 2009-2016

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9382228 - N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities (2016-07-05),

2. 9309224 - N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities (2016-04-12),

3. 9187474 - Raf inhibitor compounds (2015-11-17),

4. 9133183 - Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities (2015-09-15),

5. 8188113 - Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases (2012-05-29),

6. 7897762 - Kinase inhibitors useful for the treatment of proliferative diseases (2011-03-01),

7. 7829737 - Protein tyrosine phosphatase inhibitors and methods of use thereof (2010-11-09),

8. 7504389 - Protein tyrosine phosphatase inhibitors and methods of use thereof (2009-03-17),

Title: The Innovative Contributions of William C Patt

Introduction

William C Patt is a notable inventor based in Lawrence, Kansas, who has made significant contributions to the field of pharmaceuticals. With a total of eight patents to his name, Patt has focused on developing compounds that exhibit anti-cancer and anti-proliferative activities. His work has the potential to impact the treatment of various diseases, including cancer and autoimmune disorders.

Latest Patents

Among his latest patents is the invention of N-acyl-N'-(pyridin-2-yl) ureas and analogs. These compounds are designed to inhibit c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases, which play a crucial role in the treatment of cancer, autoimmune diseases, and metabolic bone disorders. The utility of these compounds extends to other mammalian diseases mediated by the same kinases, showcasing their broad therapeutic potential.

Career Highlights

William C Patt has worked with several prominent companies in the pharmaceutical industry, including Deciphera Pharmaceuticals and Ceptyr, Inc. His experience in these organizations has allowed him to collaborate with other talented professionals and contribute to groundbreaking research and development in the field.

Collaborations

Patt has had the opportunity to work alongside esteemed colleagues such as Daniel L Flynn and Michael D Kaufman. These collaborations have likely enriched his research and innovation efforts, leading to the development of impactful pharmaceutical solutions.

Conclusion

William C Patt's innovative work in the pharmaceutical industry, particularly in the development of anti-cancer compounds, highlights his significant contributions to medical science. His patents and collaborations reflect a commitment to advancing treatment options for serious diseases.